INDIGO Biosciences, Inc. was founded in 2005 in State College, PA. It remains a privately held biosciences company offering products and services focused on nuclear receptors, which comprise a major class of therapeutic drug targets.
The Company's two founders, Dr. Jack Vanden Heuvel and Dr. Blake Peterson, leveraged their collective expertise's in nuclear receptor biology, toxicology, medicinal chemistry and molecular biology to establish the core platform technology of The Company.
INDIGO Biosciences' original focus was that of a traditional contract research organization, namely, to provide custom services for the screening of small molecule compounds against functional human and non-human nuclear receptors. Over the years, The Company has demonstrated success in providing quality screening services to clients within the pharmaceutical, biotechnology, food, agriculture and nutriceutical industries, government research agencies, as well as to academic researchers.
INDIGO Biosciences continues to provide high-quality, confidential screening services for drug discovery and active ingredient determination.
However, in 2008 The Company's mission changed dramatically. Instead of being strictly a service provider, INDIGO Biosciences is now dedicated to establishing itself as the premier provider of cell-based nuclear receptor reporter assay products.
The technology that enabled this transformation was The Company's development of a unique and superior processing method to cryo-preserve its nuclear receptor reporter cells. This proprietary process, called CryoMite™, provides long-term cryo-preservation of cells for shipping and storage, providing users the convenience of readily available robust cell-based reporter assays for on-demand use.
Custom Assay Development
Having difficulty developing an assay? Interested in an animal model but can't find the appropriate tools? INDIGO has vast experience cloning nuclear receptors from a variety of species and developing robust whole cell-based assays. We can develop the assay under a non-propriety agreement for your use in-house or for screening in our labs.
Nuclear Receptor Reporter Assays
INDIGO utilizes cell-based, reporter assays to examine the effects of chemicals, drugs and nutrients on nuclear receptor activity. We offer over 50 different assays including human, rat and mouse orthologs of several nuclear receptors including the PPARs, LXRs, RXRα, GR and CAR.
Currently, the assessment of risk to human health from exposure to manufactured chemicals is based on
experiments performed on laboratory animals. Substantial efforts are being undertaken to develop
alternative solutions to in vivo toxicity testing that is both more predictive as well as less expensive. At
INDIGO, we embrace this new paradigm of Investigational Toxicology, based on a compound’s mode of
action, which postulates that any adverse human health effect caused by exposure to an exogenous
substance can be described by a series of causally-linked biochemical or biological key events with
measurable parameters. The objective of our ongoing research is to demonstrate the feasibility of an
integrated approach to predict human toxicity following the Adverse Outcome Pathway (AOP)
framework. For all your in vitro, investigational toxicology needs, there is only one name you need to
know. KNOW INDIGO.
"Excellent scientific engagement and communication. Excellent turnaround time. I look forward to working with you again!"
Indigo Biosciences, Inc has not received any endorsements.